Advertisement

Topics

Latest "ProCyte Corporation" News Stories

16:41 EDT 25th September 2018 | BioPortfolio

Here are the most relevant search results for "ProCyte Corporation" found in our extensive news archives from over 250 global news sources.

More Information about ProCyte Corporation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ProCyte Corporation for you to read. Along with our medical data and news we also list ProCyte Corporation Clinical Trials, which are updated daily. BioPortfolio also has a large database of ProCyte Corporation Companies for you to search.

Showing "ProCyte Corporation" News Articles 1–25 of 474

Tuesday 25th September 2018

GUERBET : 2018 half-year results

             > Sales growth at constant exchange rates > EBITDA margin in line with announced targets > Significant progress in implementing the GEAR 2023 plan Villepinte, September 25, 2018 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, has reported its consolidated half-year results, following the li...


Roche's Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer

F. Hoffmann-La Roche Ltd / Roche's Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. First Phase III study to show a cancer immunother...

Acacia Pharma Group plc: Results of General Meeting

Cambridge, UK - 25 September 2018- Acacia Pharma Group plc (the "Company") (Euronext: ACPH) is pleased to announce that both resolutions as set out in the Notice of General Meeting dated 7 September 2018 were duly passed by the required majority at the General Meeting held earlier today. The results of the votes on the resolutions are shown in the table below and will be...


Medtronic Launches the Infinity(TM) OCT Spinal System

System is Fully Integrated with Medtronic's Market-Leading Imaging and Navigation Technology to Transform Posterior Cervical Spine Surgery DUBLIN and LOS ANGELES - September 25, 2018 - Medtronic plc (NYSE:MDT) today announced the U.S. launch of the Infinity(TM) Occipitocervical-Upper Thoracic (OCT) System designed to simplify posterior cervical spine surgery. The Infinity OCT ...

FDA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome

Myelo Therapeutics GmbH / FDA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. BERLIN, GERMANY, September 25, 2018 - Myelo Therapeutics GmbH announced today that the US Food and Drug Administration (FDA) has gr...

Terveystalo Plc: Juha Tuominen, Chief Medical Officer of Terveystalo leaves the company

Terveystalo Plc Stock Exchange release 25 September 2018 at 9:00 a.m. EEST Juha Tuominen (Professor, MD, Ph.D), Chief Medical Officer of Terveystalo since 2009, has been elected as the new Managing Director of Hospital District of Helsinki and Uusimaa, starting from 1 January 2019. Terveystalo has started the search for the successor of Mr. Tuominen. Unto Palonen, senior physician of oc...

Nexstim Plc to host a Conference Call / Webcast to Present New Depression Led Corporate Strategy

Press release, Helsinki, 25 th September 2018 at 9:00 AM EEST Nexstim Plc to host a Conference Call / Webcastto Present New Depression Led Corporate Strategy Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or the "Company"), the targeted neuromodulation company developing and marketing navigated personalised, non-invasive brain stimulation systems for the treat...

DBV Technologies to Present at the Cantor Global Healthcare Conference

Montrouge, France, September 25, 2018 DBV Technologies to Present at the Cantor Global Healthcare Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Susanna Mesa, Chief Business Officer, will present at the Cantor Global Healthcare Conference on Tuesday, October ...

Monday 24th September 2018

GENFIT: Gearing Up for 2019 with Organizational Changes

GENFIT: Gearing Up for 2019 with Organizational Changes Lille (France), Cambridge (Massachusetts, United States), September 24, 2018 - GENFIT (Euronext: GNFT - ISIN: FR0004163111) today announces some key leadership changes to accompany GENFIT into the next stage of its development and its evolution from an R&D biotechnology company to a fully-integrated biopharmaceutical compan...

Pixium Vision: Positive review of the first results with PRIMA, its wireless implant, in patients with atrophic Dry-AMD

 Pixium Vision announces positive review of the first results with PRIMA, its wireless subretinal implant, in patients with atrophic Dry-AMD PRIMA could be safely implanted In all five patients, implants were successfully activated Training helps to improve quality of visual perception Paris, France. September 24, 2018 - 6.00 PM CEST - Pixium Vision (FR0011950641 - PIX),...

INVENTIVA : Inventiva launches an independent working group to help increase NASH awareness and establish best practices for its treatment

Inventiva launches an independent working group to help increase NASH awareness and establish best practices for its treatment Daix (France), September 24th, 2018 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis...

Roche's investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer

F. Hoffmann-La Roche Ltd / Roche's investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Entrectinib reduced tumours in people with ROS1-positive non-small cell lung cance...

Roche's Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer

F. Hoffmann-La Roche Ltd / Roche's Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Data will be presented at the 2018 World C...

Astrotech Reports Fiscal Year 2018 Financial Results

Astrotech Corporation (NASDAQ: ASTC) reported its financial results for the fourth quarter and fiscal year ended June 30, 2018. Thomas B. Pickens III, Chairman and CEO of Astrotech, stated, “Fiscal 2018 was an excellent year in terms of product endorsement at 1st Detect. We achieved three major milestones toward our goal of securing airport...

Galapagos reports initiation of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in osteoarthritis patients

Mechelen, Belgium, September 24 2018, 07.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports first dosing in the global ROCCELLA Phase 2 trial with GLPG1972/S201086 in knee osteoarthritis patients. Galapagos receives a €9 million milestone payment from its collaboration partner Servier for this achievement. ROCCELLA is a multiregional, randomized, double-blind, placebo-co...

Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid

F. Hoffmann-La Roche Ltd / Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Liquid biopsy test can identify 70 of the most commonly mutated genes in solid tumours, as well as microsatellite instability Many can...

Sunday 23rd September 2018

Arrayit Corporation Ships Clinical Instrumentation and Software to the United States Food and Drug Administration

Sunnyvale, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports the shipment of clinical instrumentation and quantification software to the United States Food and Drug Administration (FDA).  Arrayit uses the same instrumentation and software to test for allergy and food intolerance as well as pipeline indications for ov...

Saturday 22nd September 2018

Late-Breaking Clinical Study Results Demonstrate Exceptional Safety and Efficacy Outcomes for Resolute Onyx(TM) DES

TCT18: BIONYX Study Shows Strong Performance with Durable Polymer Resolute Onyx DES in Head-to-Head Comparison with Biodegradable Polymer DES DUBLIN and SAN DIEGO - September 22, 2018 - Investigators today unveiled new clinical data from the physician-initiated BIONYX study, representing the first all-comers analysis in nearly 2,500 patients comparing the safety and efficacy of th...

Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness

Novartis International AG / Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. In the Phase III RAINBOW study, despite marginally missing statistic...

New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD

Novartis International AG / New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Pre-specified analysis provides insight into maintenance treatment effectiveness ...

Thursday 20th September 2018

Stryker to host conference call on October 25, 2018

Kalamazoo, Michigan - September 20, 2018 - Stryker (NYSE:SYK) announced that it will host a conference call on Thursday, October 25, 2018 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ended September 30, 2018 and provide an operational update. Final operating results for the quarter ended September 30, 2018 will be released at 4:05 p.m...

Wednesday 19th September 2018

Changes in responsibility areas of the Orion Group Executive Management Board

ORION CORPORATION       STOCK EXCHANGE RELEASE      19 SEPTEMBER 2018 at 11.45 a.m. EEST                      Changes in responsibility areas of the Orion Group Executive Management Board The following changes have been decided in responsibility areas of the Orion Group Executive Management Board: As of 1 October, 2018: Mr. Markku Huhta-Koivisto,...

Monday 17th September 2018

Eve & Co Enters Into Supply Agreement With Newfoundland Labrador Liquor Corporation; Represents Third Provincial Supply Agreement

TORONTO, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (the “Company” or “Eve”) (TSXV: EVE) is pleased to announce that, through its wholly-owned subsidiary Natural MedCo Ltd., it has entered into an agreement effective as of October 17, 2018 with the Newfoundland Labrador Liquor Corporation (the “NLC”) for the distribution of various cannabis products to the adult-u...

Marrone Bio Innovations Announces Distribution Partnership with Hop Tri Investment Corporation in Vietnam

Regalia®, Grandevo® and Majestene® to Offer Vietnamese Growers Effective Biological Solutions as Regional Chemical Pesticide Reduction Begins DAVIS, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, to...

Creation of novel medicines and better patient care for the future in an ecosystem

 ORION CORPORATION                    PRESS RELEASE                 17 SEPTEMBER 2018 Creation of novel medicines and better patient care for the future in an ecosystem Orion Corporation has together with selected university research groups and other companies assembled a New Modalities Ecosystem supported by funding from Business Finland. Th...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks